WO2002060469A1 - Anticancer agents - Google Patents

Anticancer agents Download PDF

Info

Publication number
WO2002060469A1
WO2002060469A1 PCT/JP2002/000578 JP0200578W WO02060469A1 WO 2002060469 A1 WO2002060469 A1 WO 2002060469A1 JP 0200578 W JP0200578 W JP 0200578W WO 02060469 A1 WO02060469 A1 WO 02060469A1
Authority
WO
WIPO (PCT)
Prior art keywords
anticancer agents
salt
peptide fragment
agents
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/000578
Other languages
French (fr)
Japanese (ja)
Inventor
Tsukasa Seya
Misako Matsumoto
Kenichiro Naito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of WO2002060469A1 publication Critical patent/WO2002060469A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Medicinal compositions such as anticancer agents, T cell differentiation inductive cytokine-inducing agents, immature dendritic cell maturation-inducing agents and the like which contain an M161 antigen peptide fragment, its prodrug or a salt thereof; and a method of screening a substance useful as an anticancer agent, etc. with the use of M161 antigen, its peptide fragment or a salt thereof.
PCT/JP2002/000578 2001-01-29 2002-01-28 Anticancer agents Ceased WO2002060469A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-19416 2001-01-29
JP2001019416 2001-01-29

Publications (1)

Publication Number Publication Date
WO2002060469A1 true WO2002060469A1 (en) 2002-08-08

Family

ID=18885296

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/000578 Ceased WO2002060469A1 (en) 2001-01-29 2002-01-28 Anticancer agents

Country Status (1)

Country Link
WO (1) WO2002060469A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005041981A1 (en) * 2003-10-31 2005-05-12 Kurume University Combination therapy of peptide vaccination and estramustine treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP1050306A1 (en) * 1998-01-30 2000-11-08 Japan Science and Technology Corporation CYTOKINE INDUCERS COMPRISING M161Ag

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP1050306A1 (en) * 1998-01-30 2000-11-08 Japan Science and Technology Corporation CYTOKINE INDUCERS COMPRISING M161Ag

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CELLA M. ET AL.: "Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells", NATURE, vol. 388, no. 6644, 1997, pages 782 - 787, XP001079886 *
CHEMICAL ABSTRACTS, vol. 132, 2000, Columbus, Ohio, US; abstract no. 333039 *
GARCIA J. ET AL.: "A mycoplasma fermentans-derived synthetic lipopeptide induces AP-1 and NF-kappaB activity and cytokine secretion in macrophages via the activation of mitogen-activated protein kinase pathways", J. BIOL. CHEM., vol. 273, no. 51, 1998, pages 34391 - 34398, XP002203725 *
KAUFMANN A. ET AL.: "Induction of cytokines and chemokines in human monocytes by mycoplasma fermentans-derived lipoprotein MALP-2", INFECT. IMMUN., vol. 67, no. 12, 1999, pages 6303 - 6308, XP002203724 *
KEN'ICHIRO SHIBATA: "Macrophage aruiwa sen'igasaibo ni taishite cytokine yudokassei o yusuru mycoplasma no saibomaku lipo-tampakushitsu ni tsuite", NIHON SAIKINGAKU ZASSHI, vol. 55, no. 1, 2000, pages 11 - 20, XP002952458 *
MATSUMOTO M. ET AL.: "A novel protein that participates in nonself discrimination of malignant cells by homologous complement", NAT. MED., vol. 3, no. 11, 1997, pages 1266 - 1270, XP002951597 *
NISHIGUCHI M. ET AL.: "Mycoplasma fermentans lipoprotein M161Ag-induced cell activation is mediated by toll-like receptor 2: role of N-terminal hydrophobic portion in its multiple functions", J. IMMUNOL., vol. 166, no. 4, February 2001 (2001-02-01), pages 2610 - 2616, XP002951598 *
SALLUSTO F. ET AL.: "Efficient presentation of soluble antigen by cultured human dendric cells is maintained by granulocyte-macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha", J. EXP. MED., vol. 179, no. 4, 1994, pages 1109 - 1118, XP000611720 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005041981A1 (en) * 2003-10-31 2005-05-12 Kurume University Combination therapy of peptide vaccination and estramustine treatment
WO2005041982A1 (en) * 2003-10-31 2005-05-12 Kurume University Combination therapy of peptide vaccination and estramustine treatment

Similar Documents

Publication Publication Date Title
WO1999054286A3 (en) Btk inhibitors and methods for their identification and use
CA2326137A1 (en) Method for stabilizing pharmaceutical compositions by special use of an antioxidant
AU2001239182A1 (en) Semiconductor component which emits radiation, and method for producing the same
IL149136A0 (en) Compositions containing glucoronoxylomannan from basidiomycetes mushrooms and processes for the preparation thereof
AU2003269940A1 (en) Systems, methods, and compositions for achieving closure of suture sites
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
AU2002231961A1 (en) Detectable compositions, methods of forming the same and detection techniques
IL150225A0 (en) Lipopeptides, pharmaceutical compositions containing the same and methods for the production thereof
WO2003059916A8 (en) Methods for the preparation of alkyl diaryl borinates and complexed diarylborinic acids
AU4710499A (en) Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use ofsuch compounds
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
WO2001036487A3 (en) Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
WO2005037470A3 (en) Encapsulated nanoparticles, products containing the same, and methods for using the same
AU2003229835A1 (en) Compounds, compositions and method for transporting cyclosporin molecules through the blood brain barrier
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
WO2002048142A1 (en) Medicinal compositions having improved absorbability
WO2003092632A3 (en) Cyclic peptide anti-cancer agents and methods
WO2004016283A3 (en) Heteropolymeric compound comprising a scaffold, an adjuvant and an antigen, and its use
AU2003243022A1 (en) 1,2,4-triazole derivative, method for preparing the same, and pharmaceutical composition containing the same
WO2001058470A3 (en) Methods for enhancing the bioavailability of a drug
WO2004053097A3 (en) Chemopreventive and therapeutic aspects of polyphenolic compositions and assays
AU2003224019A1 (en) "water-soluble containers"
WO2000003724A1 (en) Preparations for immunotherapy for cancer having bacterial somatic constituent as the active ingredient
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
WO2002060469A1 (en) Anticancer agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP